FPA Female’s Health and wellness is the biggest independent family members preparation solution network in the USA, and also the Twirla (levonorgestrel and also ethinyl estradiol) transdermal system is currently the unique spot gave within FPA centers in The golden state
Influence of accessibility via FPA Female’s Health and wellness is anticipated to boost future non-retail network development and also add to accomplishing 2023 web income of $25-$ 30 million
PRINCETON, N.J., June 15, 2023 (WORLD WIRE SERVICE)– Agile Rehabs, Inc. (Nasdaq: AGRX), a ladies’s health care business, today introduced that Twirla will certainly appear via FPA Female’s Health and wellness. The Firm anticipates this raised accessibility to favorably influence development of need and also manufacturing facility sales in the non-retail network, which expanded 20% and also 15% specifically from the 4th quarter 2022 to very first quarter 2023.
As The golden state’s leading service provider of in-clinic and also telehealth ladies’s health care, FPA Female’s Health and wellness has 24 areas throughout Los Angeles Area and also various other areas throughout The golden state.
” We are enjoyed be the unique spot gave within FPA’s The golden state centers, and also we anticipate to use a considerable percentage of Twirla’s target populace via the FPA network,” states Principal Commercial Police officer Amy Welsh, “a link that was made with the assistance of our companions at Afaxys.”
Active remains to focus on tactical collaborations that have the prospective to successfully and also efficiently expand Twirla while concurrently permitting the Firm to properly handle its business expenses.
Concerning Agile Rehabs, Inc.
Agile Rehabs is a ladies’s health care business committed to meeting the unmet wellness requirements these days’s ladies. Our item and also item prospects are developed to give ladies with contraceptive alternatives that provide flexibility from taking a day-to-day tablet, without devoting to a longer-acting approach. Our first item, Twirla ®,( levonorgestrel and also ethinyl estradiol) transdermal system is a non-daily prescription birth control. Twirla is based upon our exclusive transdermal spot modern technology, called Skinfusion ®, which is developed to enable medication shipment via the skin. To find out more, please go to the business web site at www.agiletherapeutics.com The Firm might periodically distribute product, nonpublic info on the Firm’s web site, Twitter account (@agilether), and also LinkedIn account.
Concerning Twirla ®
Twirla( levonorgestrel and also ethinyl estradiol) transdermal system is a once-weekly mixed hormone birth control (CHC) spot which contains the energetic components levonorgestrel (LNG), a sort of progestin, and also ethinyl estradiol (EE), a sort of estrogen. Twirla is suggested for usage as an approach of birth control by ladies of reproductive prospective with a body mass index (BMI) < < 30 kg/m 2 for whom a consolidated hormone birth control is proper. Doctor (HCPs) are urged to think about Twirla’s minimized effectiveness in ladies with a BMI ≥ 25 to << 30 kg/m 2 prior to recommending. Twirla is contraindicated in ladies with a BMI ≥ 30 kg/m 2 Twirla is additionally contraindicated in ladies over 35 years of ages that smoke. Smoking boosts the threat of severe cardio occasions from CHC usage. Twirla is developed to be used when regular for 3 weeks, complied with by a week without a spot.
Positive Declarations
Particular info included in this news release consists of “progressive declarations”, within the significance of Area 27A of the Stocks Act of 1933, as modified, and also Area 21E of the Stocks Exchange Act of 1934, as modified. We may, in many cases utilize terms such as “anticipates,” “thinks,” “prospective,” “proceed,” “prepares for,” “quotes,” “anticipates,” “strategies,” “means,” “may,” “could,” “might,” “likely,” “will,” “must” or various other words that share unpredictability of the future occasions or end results to recognize these progressive declarations. Our progressive declarations are based upon present ideas and also assumptions of our administration group that include dangers, prospective adjustments in situations, presumptions, and also unpredictabilities, consisting of declarations relating to anticipated Twirla need and also development metrics, our forecasted web income and also anticipated business expenses for 2023, our continuous and also organized production and also commercialization of Twirla ®, the prospective market approval and also uptake of Twirla, consisting of the boosting need for Twirla in 2023, our collaboration with Afaxys and also its capacity to advertise development, the accessibility of Twirla via FPA Female’s Health and wellness, and also the involved boost popular for Twirla. Any type of or every one of the progressive declarations might become incorrect or be influenced by incorrect presumptions we may make or by recognized or unidentified dangers and also unpredictabilities. These progressive declarations go through dangers and also unpredictabilities consisting of dangers connected to the truth that our forecasted Twirla need and also development, web income, and also business expenses for 2023 might be wrong, our capacity to keep regulative authorization of Twirla and also the labeling under any kind of such authorization, our capacity to effectively boost the commercialization of and also raise the uptake for Twirla, the dimension and also development of the marketplaces for Twirla and also our capacity to offer those markets, regulative and also legal growths in the USA and also international nations, our capacity to get and also keep copyright defense for Twirla, and also the various other dangers stated in our filings with the united state Stocks and also Exchange Payment, including our Yearly Record on Type 10-K and also our Quarterly Records on Type 10-Q. For all these factors, real outcomes and also growths can be materially various from those revealed in or indicated by our progressive declarations. You are warned not to position excessive dependence on these progressive declarations, which are made just since the day of this news release. We take on no commitment to openly upgrade such progressive declarations to show succeeding occasions or condition.
Call:
Matt Riley
Head of Financier Relations & & Corporate Communications
mriley@agiletherapeutics.com
